发明名称 |
Treatment of jak2-mediated conditions |
摘要 |
<p>Provided is a method for treating a patient with anaemia, comprising the administration of N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-benzamide (CYT387 or momelotinib) or a related pyrimidine containing compound of the general formula (1) where the variables are defined in the specification. An example of a related compound is 4-(5-bromo-2-((4-morpholinophenyl)amino)pyrimidin-4-yl)-N-(cyanomethyl)benzamide. Further provided are an article of manufacture and a kit comprising CYT387 with a label or instructions related to the use of CYT387 in anaemia. Provided is an improved method for treating a subject having, or at risk of, a medical condition for which a JAK inhibitor is indicated, the method comprising selecting a subject that meets at least one of a number of criteria and administering CYT387 whereby the treated subject exhibits an anaemia and/or a spleen response that is improved relative to a subject not meeting any of the criteria. Further provided are an article of manufacture and a kit comprising CYT387 and a label or instructions related to the use of CYT387 in relation to the criteria of the improved method.</p> |
申请公布号 |
NZ611654(A) |
申请公布日期 |
2015.08.28 |
申请号 |
NZ20110611654 |
申请日期 |
2011.11.29 |
申请人 |
YM BIOSCIENCES AUSTRALIA PTY LTD |
发明人 |
SMITH GREGG DAVID;FIDA ROSE;KOWALSKI MARK MARION |
分类号 |
A61K31/444;A61K31/505;A61K31/506;A61K31/5377;A61K31/541;A61P7/06 |
主分类号 |
A61K31/444 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|